Dr. Lenz Describes Excitement Over Advances in GI Cancer

Video

In Partnership With:

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

Heinz-Josef Lenz, MD, the co-director of the Colorectal Center and GI Oncology Program at the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

Selecting the best treatment is specifically important for patients with colon cancer, believes Lenz. Colon cancer distinguishes itself from other types of cancer by its ability to be cured by resection. In general, Lenz notes, if a tumor does not recur within 5 years of treatment the patient is considered cured.

In other cancer types, such as breast cancer, recurrences are possible for several years following surgery, making each patient a lifetime survivor. However, in colon cancer, Lenz notes, the impact that physicians have on disease management and resection makes the difference between life and death.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology